Saltar al contenido principal
Artículo

Cálculo automático de la dermatitis atópica mediante deep learning (ASCORAD): estudio piloto

Estudio piloto de un método automatizado para calcular la gravedad de la dermatitis atópica.

Cálculo automático de la dermatitis atópica mediante deep learning (ASCORAD): estudio piloto

Automatic SCOring of Atopic Dermatitis Using Deep Learning (ASCORAD): A Pilot Study

Authors

Alfonso Medela, Taig Mac Carthy, S. Andy Aguilar Robles, Carlos M. Chiesa-Estomba, and Ramon Grimalt.

What the study evaluated

SCORAD combines several observations to measure atopic-dermatitis severity. This retrospective pilot study tested neural networks for two image-based parts of that process: estimating the affected area and rating six visual signs.

Three dermatologist-annotated image datasets were used. The two larger datasets contained only Fitzpatrick skin types I to III. A third dataset contained 112 images of skin types IV to VI and was used to examine performance on more richly pigmented skin.

Tweet by Journal of Investigative Dermatology

Reported results

For the visual-sign task, the model had a relative mean absolute error of 13.0%. For lesion segmentation, it reached an area under the curve of 0.93 on the light-skin test data. Performance was materially lower on the small skin-types IV to VI dataset, including an intersection over union of 0.32 compared with 0.64 on the light-skin test set.

ASCORAD in action

Limits

This was an image-based, retrospective pilot study, not a trial of patient outcomes or a replacement for clinician assessment. The source images came from online dermatology atlases, basic demographic data were missing, and the richly pigmented-skin test set was small. The paper presents ASCORAD as a candidate for further study, not as clinical guidance for assessing an individual patient.

Read full text

Available at https://doi.org/10.1016/j.xjidi.2022.100107.

¿Te interesa la IA médica?

Conoce Legit.Health y nuestro trabajo en inteligencia artificial dermatológica.

Explorar Legit.Health